TACE plus donafenib and immune checkpoint inhibitors for intermediate HCC (CHANCE2410 study): a propensity score matching analysis - PubMed
4 hours ago
- #TACE
- #Hepatocellular Carcinoma
- #Combination Therapy
- The CHANCE2410 study compares TACE plus donafenib and immune checkpoint inhibitors (ICIs) vs. TACE monotherapy for intermediate HCC.
- After propensity score matching, combination therapy showed superior median PFS (19.6 vs. 15.3 months), higher OS rates (1-year: 94.8% vs. 83.5%), and better ORR (78.9% vs. 62.5%).
- Combination therapy had a manageable safety profile but higher grade 3/4 adverse events (12.5% vs. 5.5%).
- Multivariate analysis identified combination therapy as an independent prognostic factor for improved PFS and OS.